Liver transplantation in autoimmune liver disease--selection of patients

• Published in: Hepato-gastroenterology Vol. 46; no. 30; p. 3053
• Main Authors: Tillmann, H L, Jäckel, E, Manns, M P
• Format: Journal Article
• Language: English
• Published: Greece 01.11.1999
• Subjects: Cholangitis, Sclerosing - immunology; Cholangitis, Sclerosing - surgery; Hepatitis, Autoimmune - immunology; Hepatitis, Autoimmune - surgery; Humans; Liver Cirrhosis, Biliary - immunology; Liver Cirrhosis, Biliary - surgery; Liver Transplantation; Patient Selection; Prognosis
• ISSN: 0172-6390

Autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are autoimmune liver diseases, which are good indications for orthotopic liver transplantation (OLT). While there is effective treatment for AIH (steroids with or without azathioprine) and PBC (Ursodesoxycholic acid) no such treatment is currently established for PSC. The need for transplantation can be delayed for AIH and PBC with appropriate therapies, while treatment options for PSC are still controversially discussed. Although the time point for liver transplantation can be roughly estimated for AIH by failure of immunosuppressive therapy and for PBC by prognostic models, the prediction of survival in patients with PSC is more difficult, and further complicated through the risk of developing cholangiocellular carcinoma (CCC). Long-term (5-year) outcome after liver transplantation approaches 80-90% for autoimmune liver diseases unless CC complicates PSC at the time of OLT. The risk of disease recurrence has been recognized for each of these entities although its clinical relevance is controversial. This gets more important as long-term survival can be achieved for most of these patients today. In this review the natural course of autoimmune liver disease will be discussed and prognostic models will be presented, which are helpful for finding the optimal time point for liver transplantation.